- Home
- RAYA vs INKT Comparison
RAYA vs INKT Comparison
Compare RAYA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAYA | INKT |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 51.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RAYA | INKT |
|---|---|---|
| Price | $4.30 | $11.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 32.8K | 19.4K |
| Earning Date | 04-17-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $3.13 | $4.56 |
| 52 Week High | $736.99 | $76.00 |
Technical Indicators
Market Signals| Indicator | RAYA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 48.90 |
| Support Level | $3.95 | $10.99 |
| Resistance Level | $4.50 | $12.27 |
| Average True Range (ATR) | 0.45 | 0.87 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 31.73 | 51.94 |
Price Performance
Historical ComparisonAbout RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.